TY - JOUR T1 - Genetics of Low Polygenic Risk Score Type 1 Diabetes Patients: rare variants in 22 novel loci JF - medRxiv DO - 10.1101/2020.10.13.20211987 SP - 2020.10.13.20211987 AU - Jingchun Qu AU - Hui-Qi Qu AU - Jonathan Bradfield AU - Joseph Glessner AU - Xiao Chang AU - Lifeng Tian AU - Michael March AU - Jeffrey D Roizen AU - Patrick Sleiman AU - Hakon Hakonarson Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/14/2020.10.13.20211987.abstract N2 - With polygenic risk score (PRS) for autoimmune type 1 diabetes (T1D), this study identified T1D cases with low T1D PRS and searched for susceptibility loci in these cases. Our hypothesis is that genetic effects (likely mediated by relatively rare genetic variants) of non-mainstream (or non-autoimmune) T1D might have been diluted in the previous studies on T1D cases in general. Two cohorts for the PRS modeling and testing respectively were included. The first cohort consisted of 3,356 T1D cases and 6,203 controls, and the independent second cohort consisted of 3,355 T1D cases and 6,203 controls. Cases with low T1D PRS were identified using PRSice-2 and compared to controls with low T1D PRS by genome-wide association (GWA) test. Twenty-six genetic loci with SNPs/SNVs associated with low PRS T1D at genome-wide significance (P≤5.0xE-08) were identified, including 4 established T1D loci, as well as 22 novel loci represented by rare SNVs. For the 22 novel loci, 12 regions have been reported of association with obesity related traits by previous GWA studies. Five loci encoding long intergenic non-protein coding RNAs (lncRNA), two loci involved in N-linked glycosylation, two loci encoding GTPase activators, and two ciliopathy genes, are also highlighted in this study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by Institutional Development Funds from the Childrens Hospital of Philadelphia to the Center for Applied Genomics and The Childrens Hospital of Philadelphia Endowed Chair in Genomic Research to HH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board and the ethics committee of the Children's Hospital of Philadelphia.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request. ER -